Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries

Recruiting Phase 2 Phase 3 Interventional Study
Angina Pectoris Microvascular Angina Vasospastic Angina Myocardial Bridge of Coronary Artery
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
150 (estimated)
Sponsor
Stanford University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing. Participants will be treated with either medications that target the underlying cause of their chest pain …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * All patients with stable angina referred to the Stanford University Hospital cardiac catheterization laboratory for clinically indicated coronary function testing are eligible for inclusion into the study. Specific inclusion criteria for randomization: * Absence of significa…
Contacts

Christopher Wong, MBBS, PhD

(650) 725 5909

ccywong@stanford.edu

CONTACT